Drug Trial Radar · NCT03327402
Safety, Tolerability and Pharmacokinetics of SHP465 in Children Aged 4 to 5 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)
Last checked: Nov 19, 2026Latest source record: Jun 8, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Mar 13, 2018
Primary completion
Oct 5, 2018
Study completion Oct 5, 2018
Sponsor
- Lead sponsor
- ShireTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Oct 31, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 4 years, up to 5 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability of SHP465 in children aged 4 to 5 years with ADHD after multiple daily doses of 6.25 milligram (mg) SHP465
Conditions
- Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
SHP465Drug
SHP465 capsule will be administered at a dose of 6.25 mg, orally once daily for 4 weeks. SHP465 is comprised of sulfate salts of dextroamphetamine and amphetamine, with dextroamphetamine saccharate and amphetamine aspartate monohydrate, which provide a composite enantiomer ratio of 3:1 d-amphetamine to l-amphetamine.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Plasma Drug Concentration (Cmax) Occurred at the Time of Maximum Observed Concentration Sampled During a Dosing Interval (Tmax) of Plasma Dextroamphetamine (d-Amphetamine) and Plasma Levoamphetamine (l-Amphetamine)Time frame: Week 4: Predose, 2, 5, 8, 12, 16, 24 hours (Day 8), 48 hours (Day 9) Postdose on Day 7
- Trough Plasma Drug Concentration Ctrough at Steady State (Ctrough,ss) of Plasma d-Amphetamine and Plasma l-AmphetamineTime frame: Predose on Day 1 and Day 28 and at 24 hours (Day 29) postdose on Day 28
- Time to Reach Maximum Observed Plasma Drug Concentration (Tmax) During Dosing Interval of Plasma d-Amphetamine and Plasma l-AmphetamineTime frame: Week 4: Predose, 2, 5, 8, 12, 16, 24 hours (Day 8), 48 hours (Day 9) Postdose on Day 7
- Area Under the Concentration-Time Curve From Time Zero to the Last Timepoint (AUC0-t) During Sample Collection of Plasma d-Amphetamine and Plasma l-AmphetamineTime frame: Week 4: Predose, 2, 5, 8, 12, 16, 24 hours (Day 8), 48 hours (Day 9) Postdose on Day 7
- Area Under the Concentration-Time Curve From Time Zero Predose to Five Hours Postdose (AUC0-5) of Plasma d-Amphetamine and Plasma l-AmphetamineTime frame: Week 4: Predose, 2, 5 hours Postdose on Day 7
- Area Under the Concentration Time Curve From Time Five Hours to the Last Timepoint (AUC5-t) of Plasma d-Amphetamine and Plasma l-AmphetamineTime frame: Week 4: 5, 8, 12, 16, 24 hours (Day 8), 48 hours (Day 9) Postdose on Day 7
- Area Under the Concentration-Time Curve From Time of Dosing to the Last Measurable Concentration (AUClast) of Plasma d-Amphetamine and Plasma l-AmphetamineTime frame: Week 4: Predose, 2, 5, 8, 12, 16, 24 hours (Day 8), 48 hours (Day 9) Postdose on Day 7
- Area Under the Concentration-Time Curve Over the Dosing Interval (24 Hours) at Steady State (AUCtau,ss) of Plasma d-Amphetamine and Plasma l-AmphetamineTime frame: Week 4: Predose, 2, 5, 8, 12, 16, 24 hours (Day 8), 48 hours (Day 9) Postdose on Day 7
- Terminal Rate Constant (Lambda z) of Plasma d-Amphetamine and Plasma l-AmphetamineTime frame: Week 4: Predose, 2, 5, 8, 12, 16, 24 hours (Day 8), 48 hours (Day 9) Postdose on Day 7
- Total Body Clearance (CL/F) for Extravascular Administration of Plasma d-Amphetamine and Plasma l-AmphetamineTime frame: Week 4: Predose, 2, 5, 8, 12, 16, 24 hours (Day 8), 48 hours (Day 9) Postdose on Day 7
- Terminal Half-life (t1/2) of Plasma d-Amphetamine and Plasma l-AmphetamineTime frame: Week 4: Predose, 2, 5, 8, 12, 16, 24 hours (Day 8), 48 hours (Day 9) Postdose on Day 7
- Apparent Volume of Distribution (Vss/F) at Steady State of Plasma d-Amphetamine and Plasma l-AmphetamineTime frame: Week 4: Predose, 2, 5, 8, 12, 16, 24 hours (Day 8), 48 hours (Day 9) Postdose on Day 7
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: From start of study drug administration up to follow-up (up to 5 weeks)
- Number of Participants With Clinically Significant Changes in Vital Signs Reported as TEAEsTime frame: From start of study drug administration up to follow-up (up to 5 weeks)
- Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Reported as TEAEsTime frame: From start of study drug administration up to follow-up (up to 5 weeks)
- Change From Baseline in Height at Final On-Treatment AssessmentTime frame: FoTA (up to Day 30)
- Change From Baseline in Weight at Final On-Treatment AssessmentTime frame: FoTA (up to Day 30)
- Number of Participants With Clinically Significant Changes in Clinical Laboratory Results Reported as TEAEsTime frame: From start of study drug administration up to follow-up (up to 5 weeks)
- Number of Participants With Overall Quality of Sleep Assessed by Post Sleep Questionnaire (PSQ) at Final On-Treatment AssessmentTime frame: FoTA (up to Day 30)
- Length of Time Awake Per Night Assessed by PSQ at Final On-Treatment AssessmentTime frame: FoTA (up to Day 30)
- Length of Time to Fall Asleep Per Night Assessed by PSQ at Final On-Treatment AssessmentTime frame: FoTA (up to Day 30)
- Length of Time Sleeping Per Night Assessed by PSQ at Final On-Treatment AssessmentTime frame: FoTA (up to Day 30)
- Total Sleep Disturbance Score of Children's Sleep Habits Questionnaire (CSHQ ) at Final On-Treatment AssessmentTime frame: FoTA (up to Day 30)
- Number of Participants With a Positive Response in Columbia-Suicide Severity Rating Scale (C-SSRS) at Final On-Treatment AssessmentTime frame: FoTA (up to Day 30)
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Preferred Research Partners
Little Rock, Arkansas
Clinical Neuroscience Solutions Inc
Orlando, Florida
Qualmedica Research, LLC
Evansville, Indiana
University Hospitals Cleveland Medical Center
Cleveland, Ohio
Ohio Pediatric Research Assn Inc
Dayton, Ohio
Professional Psychiatric Services (PPS)
Mason, Ohio
Coastal Pediatric Associates
Mt. Pleasant, South Carolina
Clinical Neuroscience Solutions Inc
Memphis, Tennessee
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.